Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Stephen D. Griffin is recorded as CFO, CEO and Board Member at Anika Therapeutics, Inc. (ANIK). Anika Therapeutics, Inc. reported in an 8-K filed June 23, 2026 that Stephen D. Griffin was appointed Class III director, effective June 18, 2026. The proxy statement of Anika Therapeutics, Inc. reports total compensation of $2,033,370 for Stephen D. Griffin in fiscal 2025, including a base salary of $500,000. Disclosed compensation is on record for 2 fiscal years. Stephen D. Griffin has spoken on 3 earnings calls across 1 company, most recently for Anika Therapeutics, Inc. on February 26, 2026.
“As a result of this vote, Mr. Fischetti, Mr. Henneman and Mr. Griffin were elected as Class III directors to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2026-01-01–present
Start not stated–present
Start not stated–present
Recorded roles and call appearances connecting this person to public companies.
CFO, CEO, Board Member
2026-01-01–present
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer | $500,000 | $2,033,370 |
| 2024 | Anika Therapeutics, Inc. (ANIK) | EVP, Chief Financial Officer and Treasurer | $278,846 | $2,646,150 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
